Results 181 to 190 of about 1,061,703 (360)

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step toward Precision Drug Monitoring

open access: yesArthritis &Rheumatology, Accepted Article.
Background Using hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring.
Shivani Garg   +42 more
wiley   +1 more source

5‐Methylcytosine Analysis of miRNAs in Minimal Change Disease

open access: yesBiotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Minimal change disease (MCD) is a glomerular disorder, which is the most common cause of nephrotic syndrome in children. Additionally, the prevalence of MCD in adults has been increasing in recent years. During protein synthesis, noncoding RNAs can be regulated through a variety of modifications, which helps preserve biological diversity and ...
Huiyi Zeng   +14 more
wiley   +1 more source

Effectiveness and safety of combining thiazides with loop diuretics vs. loop diuretics monotherapy in patients with acute decompensated heart failure: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study investigated factors associated with and outcomes of combined loop diuretics with hydrochlorothiazide (HCTZ) for acute decompensated heart failure (ADHF). Methods In this retrospective study, adults hospitalized for ADHF and who received intravenous loop diuretics between January 2016 and March 2023 were enrolled.
Chia‐Chen Hsu   +6 more
wiley   +1 more source

Population pharmacokinetic modelling revealed large variability in oromucosal absorption of Δ9‐tetrahydrocannabinol in older patients with poor appetite

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Cannabis‐based medicines are gaining interest and being explored for new therapeutic indications, many of which commonly affect older medical patients. As most previous studies of the population pharmacokinetics of cannabinoids have been performed in healthy adults, this study aimed to investigate the population pharmacokinetics of Δ9 ...
Ida Klitzing Storgaard   +12 more
wiley   +1 more source

Pharmacokinetics of teicoplanin in paediatric patients—A systematic review of current literature

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background and Objective Teicoplanin is commonly used in children to treat gram‐positive infections and is sometimes used off‐label prophylactically in surgical or paediatric oncology settings. The pharmacokinetics (PK) of teicoplanin in children exhibit considerable variability, such as in critically ill children or those with renal impairment.
Noa E. Wijnen   +4 more
wiley   +1 more source

Development and Use of Human Recombinant <sup>64</sup>Cu-rHCF as a Kidney Glomerulus-Targeted Contrast Agent for Positron Emission Tomography. [PDF]

open access: yesACS Appl Bio Mater
Baldelomar EJ   +10 more
europepmc   +1 more source

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin   +6 more
wiley   +1 more source

Large‐scale identification of genes implicated in kidney glomerulus development and function

open access: yesEMBO Journal, 2006
M. Takemoto   +18 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy